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Abstract
Rationale, aims and objectives: The diversity of types of evidence (eg, case reports,
animal studies and observational studies) makes the assessment of a drug's safety
profile into a formidable challenge. While frequentist uncertain inference struggles in
aggregating these signals, the more flexible Bayesian approaches seem better suited
for this quest. Artificial Intelligence (AI) offers great promise to these approaches for
information retrieval, decision support, and learning probabilities from data.
Methods: E-Synthesis is a Bayesian framework for drug safety assessments built on
philosophical principles and considerations. It aims to aggregate all the available
information, in order to provide a Bayesian probability of a drug causing an adverse
reaction. AI systems are being developed for evidence aggregation in medicine, which
increasingly are automated.
Results: We find that AI can help E-Synthesis with information retrieval, usability
(graphical decision-making aids), learning Bayes factors from historical data, assessing
quality of information and determining conditional probabilities for the so-called
‘indicators’ of causation for E-Synthesis. Vice versa, E-Synthesis offers a solid method-
ological basis for (semi-)automated evidence aggregation with AI systems.
Conclusions: Properly applied, AI can help the transition of philosophical principles
and considerations concerning evidence aggregation for drug safety to a tool that
can be used in practice.
K E YWORD S
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1 | INTRODUCTION
Every day, doctors, hospitals, pharmaceutical companies, and others in
healthcare face the complexities of the human body and the
healthcare environment. There are huge masses of diverse possibly
relevant data which, if harnessed properly, can improve the quality of
treatment, and if used poorly, can lead to disasters like thalidomide
and Lyodura. Given the challenge of interpreting such varieties of
data, it is clear that AI has an important role to play in healthcare. In
fact, it has already had a major impact. Telehealth agencies such as the
NHS 24 Self-Help guide* use automated reasoning to help patients
self-diagnose. An AI system powered by Google LLC predicted hospi-
tal inpatient death risks with 95% accuracy.1 In January 2020, the first
AI-developed drug, DSP-1181 (a treatment for obsessive compulsive
disorder) entered clinical trials.† AI can also make a contribution to
diagnostic procedures by doctors2 (see Amato et al3 for a general
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overview of AI for medical diagnoses). The idea of a ‘smart’ hospital,
with programs and devices coordinated by AI, is no longer just science
fiction.4 AI also has roles to play in identifying drug interactions, inter-
preting possibly minute details in images, logging and processing
health records, and more. Still, rigorous research into the performance
of AI in many of these areas is still in its infancy.5,6 AI's use for public
health more widely is at more of a prospective stage, but its potential
is obvious.7
In this article, we focus on pharmacosurveillance. We explore how
AI can contribute to the continuous assessment of putative Adverse
Drug Reactions (ADRs). This manuscript is organized as follows: in the
Methods section, we briefly present E-Synthesis, a framework for com-
bining different types of evidence in pharmacovigilance, based on
Bayesian epistemology, as well as AI methodology for evidence aggre-
gation in medicine. In the Results section, we show how E- Synthesis
and AI can be intertwined to the benefit of both. Finally, in the Discus-
sion section, we offer some concluding remarks and provide an outlook
on a possible research agenda in drug safety assessment.
2 | METHODS: E-SYNTHESIS AND AI
The synthesis of evidence from multiple sources providing different
kinds of information (randomized studies, observational studies, case
reports, in vitro evidence), with the aim of evaluating hypotheses and
making decisions, plays a fundamental role in in many areas of medi-
cine. In pharmacosurveillance, for instance, relevant evidence only
becomes available in an unsystematic and motley way, so that evalu-
ating hypotheses is far from the textbook ideal of interpreting a neat
result from a randomized controlled trial (RCT). Thus, there is a need
for methods of synthesis that assess the significance of heteroge-
neous evidence in a systematic, well-grounded, and manageable way.
Since traditional frequentist statistical methods struggle with aggre-
gating different kinds of information, a more flexible approach is
required here. We next present a Bayesian approach to drug safety
assessment, and then we outline how AI methods can serve evidence
aggregation. The interaction between AI and this Bayesian approach
will be explored in the Results section.
2.1 | E-Synthesis: Bayesian epistemology for
evidence aggregation in pharmacovigilance
E-Synthesis is a Bayesian framework for evidence aggregation in
pharmacosurveillance to support timely decision making based on all
the available ‘safety signals’.8-12 The framework rests on Bayesian
epistemology, which unlike Bayesian statistics enables representation
of and reasoning with uncertainties attaching to arbitrary
propositions.
In previous papers, we have presented its philosophical
foundations,8 studied the incorporation of evidence qualities,11 inves-
tigated the aggregation of knowledge concerning biological mecha-
nisms and dose-response,9,10 and made strides towards applying E-
Synthesis in personalized medicine.12 In this subsection, we give a
brief overview of E-Synthesis.
2.1.1 | Motivation and goal
The risk-benefit profile of a drug is assessed and updated throughout
the development process: after its formula is proposed, during its syn-
thetization, and in the post-marketing period. There is no point at
which its safety is definitively established: its developers and drug
regulators must make multiple judgements at different phases of
development, using heterogeneous evidence, such as whether to
withdraw the drug. Currently, these decisions are made using system-
atic reviews that combine the wide variety of available evidence (pre-
clinical studies, clinical trials, spontaneous reports, basic research etc.)
to justify or undermine hypotheses about the presence or absence of
causal relations between the drug and harms. However, it is difficult
to combine heterogeneous data with various sources, modalities
(observational vs experimental) and different degrees of external and
internal validity. The ultimate objective of E-Synthesis is to surmount
this difficulty, by providing a systematic, epistemologically principled,
and usable method for combining evidence.
This framework rests on the paradigmatic philosophical account
of uncertain inference (Bayesian epistemology) in order to provide a
theoretically justified probability of a drug causing a harm on the basis
of all the available evidence. It employs a Bayesian network13 incorpo-
rating indicators of causality derived from the Bradford-Hill guide-
lines14 as well as evidence qualities and uncertainties attaching to
these evidence qualities. Unlike the GRADE approach, which is not
straight-forwardly applicable to decision problems,15 the probability
produced by E-Synthesis has been designed to be used for making
decisions via the maximization of expected utilities.
2.1.2 | Bayesian networks
In order to have an inferential mechanism that can handle heteroge-
neous types of evidence, E-Synthesis utilizes the tools of Bayesian net-
works and Bayesian epistemology. We provide a brief introduction to
these ideas and the rationale of their implementation in E-Synthesis.
Bayesian epistemology is a philosophical theory about (a) what
sort of beliefs and strength (‘degree’) of beliefs can be rational in a
particular context and (b) how those beliefs should be revised upon
learning new evidence. Bayesianism formalizes degrees of beliefs as
probabilities; it thereby inherits the formal constraints of the probabil-
ity calculus. Thus, P(H) represents a researcher's degree of belief in a
hypothesis, while P H Ej Þð represents their degree of belief in H condi-
tional on acquiring evidence E . In the case where our hypothesis is
that of the drug causing an ADR (denoted by ©), this conditional prob-
ability can be determined using Bayes' Theorem:
P ©jEð Þ= P ©ð Þ P Ej©ð Þ
P ©ð Þ P Ej©ð Þ+PNi=2P Hið Þ P E Hij Þð
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where the hypotheses Hi and © = H1 constitute a mutually inconsis-
tent and exhaustive partition.‡
With this mathematical formula, the posterior probability of the
hypothesis given the evidence, P © Ej Þð , only depends on prior proba-
bilities P(Hi), and likelihoods P E Hij Þð .§ Bayesian epistemology focuses
on updating (or “conditionalizing”) for propositions or events in gen-
eral, whereas Bayesian statistics focuses on testing statistical models
using conditional probabilities.
It is generally very difficult to calculate conditional probabilities
directly or to make a long and complex series of inferences using
them. Bayesian networks offer a convenient means for graphically dis-
playing and reasoning with probability functions.13,16 We can use
them to specify and read-off conditional independencies from a graph.
Technically, a Bayesian network is defined on a set of pairwise differ-
ent variables by a directed acyclic graph (which means that the edges
are directed such that the graph does not contain a directed cycle,
that is, it has no path of directed edges which leads back to its starting
point). Secondly, a probability distribution specifying the conditional
probabilities of all variables given their parent variables (all other vari-
ables which directly point to this variable). See Figure 1 for an exam-
ple graph.
Technically, this works as follows. Denoting the parents of a vari-
able Y by X1, …, Xn one specifies P(Y = yj X1 = x1, …, Xn = xn) ∈ [0, 1]
for all possible values y, x1, …, xn under the condition that
P
y ∈ YP
(Y = yj X1 = x1, …, Xn = xn) = 1. This condition ensures that we have
defined a probability function that satisfies the standard probability
calculus. To calculate conditional and unconditional probabilities of
interest, one may use the so-called ‘chain rule’.
2.1.3 | Indicators of causation
Bayes' theorem is essential in Bayesian epistemology, but it is by no
means clear how to determine the likelihoods P E Hij Þð in
pharmacovigilance. To facilitate this task, we employ abstract indicators
of causality that are derived from Bradford Hill Guidelines: (a) difference
making, (b) probabilistic dependence, (c) dose-response relationship,
(d) rate of growth, (e) temporal precedence, and (f) mechanistic knowl-
edge. Conceptually, indicators of causality are testable (probabilistic)
consequences of the causal hypothesis. For example, we can test
whether there is a dose-response relationship between a drug and an
adverse effect, such that higher dosages lead to a more and/or stronger
adverse effect. However, note that a causal relationship might lack a
dose-response relationship (anaphylaxis) and a dose-response relation-
ship might exist without a causal relationship, due to confounding. The
indicators are probabilistic consequences in the sense that their truth is
more likely, if the hypothesis is also true, than if the latter is false, that
is, P Ind ©j Þ>P Indð Þ>P Ind ©  . In turn, P © Indj Þ>P ©ð Þ>P © Ind  .
Therefore, there is an association between each relevant experi-
mental study, observational study, case series, case report or basic sci-
ence finding with a set of causal indicators which it is informative
about.8,11,17 E-Synthesis thus analyses the inferential process from the
raw data to the hypothesis that a causal link holds between a drug
and an ADR into two steps: (a) from data (study reports) to causal indi-
cators and (b) from causal indicators to causality.
A core idea of Bayesian epistemology is that the confirmatory
value of evidence with respect to hypotheses is degree-valued. The
same holds here with respect to evidence for or against our causal
indicators. We use evidential modulators to make this fine-grained
and incremental element in Bayesian reasoning explicit, by determin-
ing the quality of evidence as a function of various choices in study
design and data analysis (blinding, randomization, sample size, study
duration, stratification), see Figure 1.
2.1.4 | Evidential modulators
One key feature of E-Synthesis is the possibility of assessing the qual-
ity of items of evidence. The assessed quality of evidence then modu-
lates the degree to which the item of evidence (dis-)confirms
indicators of causation. This is achieved by first creating a ‘report’ var-
iable, Rep, for every item of evidence and then creating for every such
variable a set of pertinent modulator variables Q1, …, Qk, for example,
duration of a study, sample size and blinding. In the Bayesian network,
these modulator variables are, together with a set of indicator vari-
ables, the parents of the report variable. According to the Bayesian
approach one then needs to set the conditional probabilities of
observing the evidence given their qualities and given the values of
the indicator variables, P(Rep = repj Ind = ind, Q1 = q1, …, Qk = qk).¶
An application of Bayes' Theorem enables one then to calculate the
posterior probability of causal indicators. In turn, this posterior probabil-
ity can be used to calculate the posterior probability of the causal
hypothesis that the drug causes an ADR in the population of interest.
F IGURE 1 Graph structure of the Bayesian network for one
randomized controlled trial (RCT) which informs us about difference
making (Δ) which in turn informs us about the causal hypothesis. The
information provided by the reported study is modulated by how well
the particular RCT guards against random and systematic error. The
evidential modulators for an evidence report are SS, Sample Size; D,
Study Duration; A, Adjustment for covariates or subgroup analyses
and the like; SB, Sponsorship Bias; B, Blinding; and R, Randomization11
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2.2 | AI and evidence aggregation in medicine
As outlined in the Introduction, AI already has a growing impact on
healthcare. However, its potential for evidence synthesis is still under-
developed.** This is despite cautious interest within parts of the
healthcare industry.†† Greater use of AI in evidence synthesis could
have many benefits, which we detail in Section 4.2.
We stress that the automation of the entire evidence synthesis
process is not a currently realistic goal. Instead, a plausible ambition is
what has been called ‘semi-automated evidence synthesis’20 in which
parts (perhaps even a majority) of the evidence synthesis process are
automated using AI software. This would make evidence synthesis
more manageable and transparent, while preserving vital roles for
human judgement in many parts of the process. Some researchers are
already pursuing such goals on a grand scale.21
The semi-automation research program has already produced
some results. For instance, inference of causality from heterogeneous
data have been explored,22 so as semi-automatic transferring of
knowledge from one field to another by analogy.23,24 Moreover, spe-
cific efforts have been deployed on machine learning. Machine learn-
ing focuses on computer algorithms such that the computers can
perform tasks without being expressly compiled to do as such. This AI
field utilizes different methodologies. There is a particular interest in
two perspectives: supervised and unsupervised learning.25 Supervised
learning algorithms build a mathematical model of a set of data that
contains both the inputs and the desired outputs. Through iterative
optimization of an objective function, supervised learning algorithms
learn a function that can be used to predict the output associated with
new inputs. An algorithm that improves the precision of its outputs
after some time is said to have learned how to play out that task. In
contrast, unsupervised learning algorithms take a set of data that con-
tains only inputs, and find structure in the data, like grouping or clus-
tering of data points. The algorithms, therefore, learn from test data
that has not been labelled, classified or categorized. Unsupervised
learning is usually considered the most advanced edge of research in
this field. For example, machine learning methods like text mining can
help to screen studies for relevance.26 There is also research on auto-
mating the extraction of relevant data from particular studies.27 It
might even be possible to create what has recently been dubbed ‘liv-
ing systematic reviews’: once an evidence synthesis has been com-
pleted, there will be automated identification of relevant subsequent
research and extraction of the data that directly addresses the subject
of the evidence synthesis. Human input would only be required to
check the results of this process (which will be imperfect) once it has
been completed.28
3 | RESULTS
In this section, we explore in detail what may come out from the inter-
actions of E-Synthesis and AI. We investigate both directions, that is,
what E-Synthesis can provide for a better working of AI and how AI
itself can improve E-Synthesis.
3.1 | E-synthesis for AI
As outlined in the previous section, E-Synthesis offers a methodologi-
cally sound approach for evidence aggregation tasks in general. The
methodological choice of a Bayesian network lends itself to further
applications in AI, since Bayesian network algorithms are designed to
be easily implemented within AI systems. Moreover, we deem that E-
Synthesis can contribute to strengthen AI use in digital health applica-
tions at least in two ways:
1. It is a formal evidence synthesis procedure. Hence, the procedure
should ultimately be amenable to semi-automation.
2. Its Bayesian basis aids transparency. The Bayesian methodology
requires that we define the prior probabilities of possible events
and their interrelations within our model, as a precondition of mak-
ing inferences using E-Synthesis. The elements of this process are
standard Bayesian tools, adapted to the particular case of pharma-
cological evidence synthesis. Therefore, prior to applying E-Synthe-
sis, we must articulate our assumptions in a way that those familiar
with Bayesian modelling can understand them.
We shall expand on the second point. A significant concern in
contemporary AI design is transparency, especially for AI involved in
decisions that affects people's lives. Where possible, it is ethical that
decision-making processes are understandable for the people affected
by them, so that these people can enter into the relevant delibera-
tions, articulate their own viewpoints in an informed manner, and oth-
erwise hold AI designers to account. For instance, if an AI algorithm
has features that systematically bias decisions against a particular race
or gender, we want this bias to be open to challenges by the groups
who are negatively affected or experts working on their behalf. The
extent to which AI is understandable for users and stakeholders will
vary among contexts, but even when users lack the expertise required
to understand some AI's reasoning, the comprehensibility of that rea-
soning is often possible for experts who are accountable to those
users. Transparency of an AI's decision-making process widens the
scope of users and stakeholders who can understand (directly or indi-
rectly) the system and the depth of their understanding.
However, some types of AI have limited transparency even for
those with relevant expertise. For example, recently, concerns have
been raised with respect to medical decision algorithms.29-32 Many
early applications of computer reasoning in AI used relatively simple
if-then reasoning procedures, where the link between the inputs and
the decisions was clear.33,p. 3032 Yet machine learning functions that
use neutral networks are distributed over all the neurons, with no
unique functional form. The neural network approach offers great
gains in the accuracy of inferences made using the AIs, but at the cost
of relatively low transparency.
By contrast, the decisions about drug safety that are made by E-
Synthesis will ultimately be formalizable in algorithms. It is true that
there could be some exogenous elements. One example is that, at the
input level, the selection of data for the evidential modulators could
be decided by non-transparent neural network machine learning. At
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the output level, we are not proposing the complete automation of
drug safety decisions, but instead just semi-automation, and therefore
there will still be human judgements that could be opaque, depending
on how the regulators make their choices.
However, E-Synthesis shares a common Bayesian advantages that
it forces us to make our probabilistic assumptions explicit, and thus
open to criticism.34,Chapter 11 Therefore, in comparison to some types
of AI, using E- Synthesis would improve transparency. Note that this
superior transparency holds even if we think that the priors are ulti-
mately ‘subjective’ in an epistemological sense: users can still raise
challenges on criteria such as alignment of the prior probabilities with
well-tested physical probabilities, the liability of priors to help us avoid
catastrophic choices,35 and other desiderata that users might have for
priors.
For the capacity of E-Synthesis to improve pharmacological pre-
dictions, we can point to some promising precedents in which AI has
been used to improve predictive power.36,37 AI is especially promising
for orphan drugs38 where the quantity and quality of data cannot
compare with largely used medications. We think that E-Synthesis may
contribute in improving these AI methods with a more sophisticated
evidence aggregation and evaluation, favouring a better understand-
ing of causal underpinnings in drug safety management.
3.2 | AI for evidence synthesis
As we have seen, AI methods are already employed in the realm of
evidence aggregation and may effectively contribute to a better func-
tioning of E-Synthesis (Section 2.2). That framework puts forward a
decision-making model to support drug safety assessments, which are
usually performed in a collective way by advisory committees, panels
of experts consulting drug agencies.39 However, significant parts of E-
Synthesis are still left to experts and are not automated. For instance,
the strengths of how strongly different evidential modulators
(Section 2.1.4) influence confirmation is still input manually by the
introduction of an ad hoc weighting scheme. The application of
machine learning and other AI techniques could lead to remarkable
improvements of the quality of decisions.
In the following, we pin down three main areas of interaction
between E-Synthesis and AI: machine learning, information retrieval
and graphical decision aids. We conclude that evidence synthesis for
pharmacosurveillance can be enhanced by AI, (cf. Section 4.2).
3.2.1 | Machine learning
Machine learning can greatly strengthen E-Synthesis, creating auto-
mated systems that make better use of the vast amount of accumulat-
ing publications and promoting the uptake of that evidence into a
wide range of contexts. Using machine learning, E-Synthesis will be
enhanced in identifying, extracting, synthesizing and interpreting rele-
vant information, converting this into knowledge that can answer
complex questions over causal associations. We identify two main
applications of machine learning for improving E-Synthesis:
(a) estimation of conditional probabilities of causal indicators and
learning the weighting schemes of the evidential modulators from
data and (b) modelling the ‘linkage between a direct molecular initiat-
ing event […] and an adverse outcome at a biological level of organiza-
tion relevant to risk assessment’.40,p. 731 The latter occurs through an
adverse outcome pathway (AOP), that is, a conceptual construct—
expressed in terms of flow-charts—that portrays existing knowledge
concerning the linkage between that initiating event at a molecular
level and the adverse outcome that can be macroscopically observed.
Such ‘mechanisms’ play an important inferential role.41
3.2.2 | Assessing probabilities and predictive
powers
As shown above, E-Synthesis delivers a probability of causal associa-
tion between a drug and an ADR, based on a Bayesian updating of
evidence that accrues through causal indicators. Machine learning
could help E-Synthesis in:
Learning the weighting scheme of the evidential modulators
The task determining how likely it is that a study (observational or an
RCT) correctly identifies the absence or presence of a causal relation-
ship between a drug and an ADR given the characteristics of the study,
for example, duration and sample size. Machine learning can be used to
estimate frequencies from past studies, since we know whether the
causal link was present and the values of the modulator variables.
Note that, while machine learning can help us to obtain values for
the evidential modulators, we still face ‘The Problem of the Reference
Class’: the challenge of selecting the set of studies from which to infer
these frequencies.42 Which studies should we learn these frequencies
from? Do we include all studies of the same/similar drug, similar/same
adverse event (reaction), same type of sponsor of study (commercial or
institutional),43 beneficial and/or adverse effects? There does not seem
to be an obvious answer. Considering only studies which are similar to
the study under consideration leads to a small set of specific studies
(little but specific data) while considering many, some of which less
similar, studies leads to a large set of studies (much but unspecific data).
Ample data is the tool of choice to decrease statistical noise while spe-
cific data helps ensuring that the actual phenomenon of interest is
studied. In our world of limited specific data, it is impossible to say how
to optimally strike a balance between the value of these tools in gen-
eral. However, a Bayesian framework like E-Synthesis helps us make
our answers to the methodological questions (in the form of our Bayes-
ian probabilities for particular events) more rigorously formulated and
open to scrutiny than if choice among reference classes is left implicit.
Learning the conditional probabilities of indicators of causation
The goal is to estimate the conditional probability of an indicator vari-
able given © or its negation (and its other parent variables, if there are
any). The predictive power of the causal indicators may be inferred
from past drugs with a suspected ADR, such that (1) we now know
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whether each of those drugs causes the ADR and (2) which of the
indicators they had. Concrete learning applications again face a refer-
ence class problem. The set of causal indicators was distilled from
Hill's Guidelines and the set of modulators was determined from a
study of current medical methodology literature. E-Synthesis has
always been developed with future possible modifications of these
sets in mind. Unsupervised machine learning algorithms may discover
further predictors, which could give rise to new indicators and/or evi-
dential modulators. Possible new predictors might include the number
of authors of published study and/or affiliation of the study's authors.
3.2.3 | Modelling mechanisms
Machine learning could play a fundamental role also in modelling
mechanisms within E-Synthesis. There is already an abundant literature
on its use in pharmacokinetics and pharmacodynamics44,45 to figure
out possible and impossible biochemical mechanisms, bypassing
in vitro and in vivo checks by fast and efficient deployment of in silico
analyses. Likewise, a better understanding of absorption, distribution,
metabolization mechanisms—which prove critical for dose-response
and drug concentration estimation in drug delivery processes—has
been highly accelerated by computer simulations46 and machine learn-
ing.47,48 Some steps towards such a direction have been already taken
in Abdin et al9 and De Pretis and Osimani,10 where—in the latter—
dose-response algorithms, usually employed in clinical phase II, have
been translated to pharmacovigilance.
3.2.4 | Information retrieval
Given larger and larger amount of publications available, the need for
advanced information retrieval (IR) systems increases. AI may also help
here. At present, most IR systems, such as general search engines (eg,
Google and Yahoo) and scientific literature search engines (eg, PubMed
and ACM Digital Library), use keywords to query and index documents.
However, this traditional keyword-based IR model provides little
semantic context for the understanding of user information needs. For
example, a keyword usually has several senses and its meaning is
ambiguous without context. In addition, one meaning can be expressed
by many keywords.49 There is a long-running research program of try-
ing to addressing these problems.50,51 The push towards integration of
semantic context according to the user's information need and the
user's understanding of documents in the collection into IR systems is
one of the main topics of current IR research.49 On the medical side,
knowledge extraction may prove fundamental for accelerating the
bench to bedside passage in pharmacological research.52 With respect
to E-Synthesis, evidence retrieval may boost its performances, by query-
ing databases for all known names for a drug (alike what is done in
databases like VigiBase‡‡), for similar drugs (similarity in terms of active
ingredient, drug carrier, chemical structure) and similar reactions, as well
as disentangling mechanisms of putative causal connections with
respect to different drugs causing the same ADR.§§
3.2.5 | AI-powered graphical decision aids
Facing an increasing amount of information puts pressure not only on
the way such data must be analysed,54 but also on the way those data
have to be presented for an effective decision making. In fact,
researchers with limited information processing capability are usually
unable to cope with an exponentially increasing amount of informa-
tion, leading to a phenomenon called ‘information overload’. This phe-
nomenon has widely been recognized to have adverse effects on
decision quality.55 The use of graphs as decision aids to reduce the
adverse effects of information overload on decision quality has been
positively investigated both in management56 and communicating
risks between patients and physicians.57 AI could aid these goals by
making it easier to visualize the confirmatory impact of (hypothetical)
evidence and the confirmatory impact of indicators. An interactive
graphical representation of strengths of associations may lead to bet-
ter decisions based on E-Synthesis.
4 | DISCUSSION
We have shown how AI may contribute to pharmacovigilance by
improving a Bayesian framework for evidence synthesis. We think
that such applications will also benefit other approaches to evidence
synthesis. The prospects for AI supported inference in medicine seem
bright, yet we stress that AI will not cure all ills.
4.1 | Limitations: AI is not a panacea
AI can reduce some of the limitations of E-Synthesis, yet some will
remain. For instance, while machine learning can help in making the
weighting scheme of evidential modulators, as well as the probabilities
of the causal indicators more objective, it is still a human who chooses
the algorithm for these machine learning operations. There will hence
continue to be room for subjective choice and disagreement about
these choices. Furthermore, while graphical decision aids can improve
the usability and explainability of decision processes, good decision
making under uncertainty is a complicated task at which we routinely
fail to be optimal.58
One current limitation of E-Synthesis is its concept of causation.
Consider the (simplified) case of taking a drug D and an adverse drug
reaction A. Currently, E-Synthesis treats causation as categorical and
binary: either D causes A or it does not. This reflects the traditional
approach to causation in philosophy.59-64 For some decisions, binary
causation might be sufficient: for example, if we regard a causal rela-
tion from D to A as sufficient for rejecting the use of D in medicine,
then all we need to determine is the presence or absence of that
causal relation. However, policymakers, doctors, patients and scien-
tists are often interested in the question of the strength of a causal
relation. E-Synthesis does not commit us to any particular account of
causal strength. There are many options in the literature that might be
explored.65-69
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4.2 | AI and human judgements
We have assumed that that AI can improve human decision making.
While we do not think that AI always improves our decision making,
there are good reasons and evidence that, in medicine, AI is already
improving decision qualities and that AI support will lead to even bet-
ter decisions in the future.
Firstly, AI can perform tasks on large data sets we are simply not
able to do, for example, searching, summarizing and revising probabil-
ity distributions. AI thus expands the computational capacity of evi-
dence evaluators. The accelerating increase in medical data means
that the application of AI in evidence synthesis is increasingly difficult.
Insofar as evidence syntheses depend on a lot of human input, it will
be hard to keep track of the ever-greater flow of evidence such as
case reports and clinical trials. Automation via AI can help alleviate
some of these information processing strains in the evidence synthe-
sis process.
Secondly, AI can make the decision-making procedure more
transparent. Such systems can offer graphical decision aids which
can be used by evidence evaluators when explaining their decisions
to patients, policymakers, and other stakeholders. Additionally, all
outputs of AI systems depend ultimately in a formal and
(in principle) traceable matter on the input. In some cases, AI rea-
soning can be summarized in terms of algorithms that are accessible
for many users and groups affected by the reasoning. Human
decision-making procedures are by contrast most often not open to
inspection.
It is true that the superior transparency of AI is not guaranteed.
We noted above that machine learning systems are often incompre-
hensible, in some sense, even for experts. Yet, even in these cases,
it is not clear that AI is any less transparent than human reasoning,
since the latter might involve intuitive judgements that are also
impossible to articulate formally.70,p. 7 Furthermore, while a neural
network's learning algorithm might have no explicit representation,
the network's overall dynamics can be articulated and scrutinized—
something far beyond what we can currently do with the
human mind.
Thirdly, AI offers us the possibility to better understand our
judgements by performing hypothetical analyses of how different
judgements influence decision-making procedures. Let us recall the
Reference Class Problem (Section 3.2.1). Applying AI systems to dif-
ferent reference classes allows us to perform sensitivity analyses,
thereby shedding light on how our judgements of relevance influence
decision making. Depending on our answer to the Reference Class
Problem, such analysis might even help in finding an appropriate ref-
erence class.
4.3 | Future work
While we can understand causal relations between binary variables
by how much (in some sense) the presence of the cause variable cau-
ses the probability of the effect variable to increase, there is also a
pertinent graded sense of causation between many valued variables:
how strong an ADR does a particular dosage cause? AI holds great
promise to squeeze such more fine-grained information from evi-
dence, which will require continued interaction between stakeholders
and scientists from numerous areas. We echo the call for an increase
of such interactions to improve pharmacovigilance for the good of us
all.9,71,72
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‡ For convenience, we use the same symbol denoting a variable and the
variable being true.
§ In basic statistical applications of Bayesianism, the likelihoods are often
(but not always) easy to determine, because the content of the hypothe-
sis will often determine a probability for the evidence due to logical or
mathematical reasons. For example, if a hypothesis (with a non-zero
prior probability) implies the evidence, then the likelihood must be
1. Meanwhile, determining the likelihood of the evidence given a statisti-
cal hypothesis Hi often just requires using purely mathematical reason-
ing, for example, calculating the probability of a particular series of
independent and identically distributed binomial trials given the hypoth-
esis of a population frequency. However, in more complex applications,
determining the likelihoods can be very difficult, as we discuss later.
¶ Uncertainty about study qualities is represented by probabilities in the
fashion usual in Bayesian statistics, for example, P(Qi = qi).
** The first automated evidence synthesis system was only published in





§§ There are known examples of linking different drugs to the same
ADR[53]. Such evidence can help to exonerate a drug under consider-
ation by putting the blame on a different drug causing the ADR. How-
ever, such evidence may also incriminate the drug under consideration
by elucidating the mechanism between the drug under consideration
and the ADR.
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